EnWave CEO Brent Charleton Provides Clear Picture of Current Situation and Outlook
It has been a while since we provided an update on EnWave Corporation (CA:ENW – $0.93 & US:NWVCF – $0.72 & GER:E4U – €0.59), so we were pleased to sit down with Mr. Brent Charleton, the Company’s President and CEO.
The interview first touches upon EnWave’s financials and how COVID-19 caused sales and earnings to decline in the first nine months of fiscal year 2020. Mr. Charleton provides details on several new TELOA’s and royalty bearing agreements that were signed the past few weeks despite COVID-19.
In addition, the CEO delivers plenty of valuable information about the medical and pharmaceutical side of the business. Last week, the Company announced a collaboration with the University of British Columbia to investigate a manufacturing method for a new inhaler with the goal of providing relief for COVID-19 patients. Furthermore, an update is provided on the project with Merck and the agreement with GEA Lyophil of Germany.
Moon Cheese also receives plenty of attention in the interview as Mr. Charleton discusses the national promotion, which is on the way at Costco next month. Moreover, the CEO touches upon the expansion of distribution of Moon Cheese into other retailers.
A substantial portion of the interview is devoted to cannabis. Expectations are discussed from the recently completed installation of a 60kW processing line at The Green Organic Dutchman. Mr. Charleton updates listeners on the progress at other major cannabis players, such as Aurora and Tilray, and he also describes how the U.S. cannabis and hemp market is developing for EnWave.
Finally, Mr. Charleton talks about the current status of the agreement with the U.S. Army.
Access our interview by clicking the play button on the media player below.
|For important disclosures, please read our disclaimer.||Latest Company Report (pdf)|